Short answer
Editas Medicine, Inc. (EDIT) filed an 8-K current report with the SEC on May 14, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). EDIT disclosed new preclinical EDIT-401 data for potential hyperlipidemia treatment.
Editas Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- EDIT disclosed new preclinical EDIT-401 data for potential hyperlipidemia treatment
- Data presented at the American Society of Gene and Cell Therapy 2026 Annual Meeting
- Investor focus: EDIT-401 development progress remains preclinical, with clinical readiness and efficacy still unestablished
Item 8.01 · Other Events
- EDIT-401 achieved at least 90% mean LDL-C reduction in non-human primates after a single dose
- LDL-C lowering persisted approximately six months across 1.5–3.0 mg/kg doses
- Only 10–40% functional LDLR editing produced at least sixfold higher hepatic LDLR protein
- No adverse clinical observations at the therapeutically relevant 1.5 mg/kg dose
- Preclinical data support potential one-time treatment for hyperlipidemia and advancement toward HeFH studies
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Editas Medicine, Inc. 8-K filings
Get the next EDIT 8-K as it lands
Follow EDIT for push alerts, or ask the research agent what this filing means.